Trial Profile
Topical Imiquimod in Treating Patients with Persistent HPV-Infection after Surgical or Radiation Treatment of Cervical Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2016
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary)
- Indications Human papillomavirus infections
- Focus Therapeutic Use
- Acronyms TACTIQ
- 02 Sep 2016 Status changed from recruiting to discontinued.
- 22 Jun 2011 New trial record